44:20:01:04. Category II reportable diseases and conditions. Category II reportable diseases and conditions include:
(1) Acute flaccid myelitis;
(2) Anaplasmosis (Anaplasma phagocytophilum);
(3) Arboviral encephalitis, meningitis or infection (Eastern equine, Western equine, California serogroup, St Louis, Japanese, Powassan, West Nile virus, Chikungunya, Colorado tick fever, Zika virus);
(4) Babesiosis (Babesia spp);
(5) Campylobacteriosis (Campylobacter spp.);
(6) Chancroid (Haemophilus ducreyi);
(7) Carbon monoxide poisoning;
(8) Chicken pox/Varicella (herpesvirus);
(9) Chlamydia infections (Chlamydia trachomatis);
(10) Cholera (Vibrio cholerae);
(11) Cryptosporidiosis (Cryptosporidium parvum);
(12) Coccidioidomycosis (Coccidioides spp);
(13) Cyclospora (Cyclospora cayetanensis);
(14) Dengue viral infection (flaviviruses);
(15) Drug resistant organisms:
(a) Vancomycin-resistant Staphylococcus aureus (VRSA);
(b) Carbapenemase-producing organisms;
(c) Candida auris;
(16) Ehrlichiosis (Ehrlichia spp.);
(17) Giardiasis (Giardia lamblia);
(18) Gonorrhea (Neisseria gonorrhoeae);
(19) Haemophilus influenzae, invasive disease;
(20) Hantavirus pulmonary syndrome and Hantavirus infection (Hantaviruses);
(21) Hemolytic uremic syndrome;
(22) Hepatitis, viral types A, B, and C, including all molecular Hepatitis C results;
(23) Human immunodeficiency virus (HIV) infection; including:
(a) AIDS (Stage III infection);
(b) CD4 counts in HIV infection persons;
(c) HIV viral loads;
(d) Pregnancy in HIV-infected females;
(e) HIV gene sequencing;
(f) HIV antiviral resistance; and
(g) Confirmatory results, positive or negative, following a reactive HIV screening test;
(24) Influenza:
(a) Laboratory-confirmed cases;
(b) Influenza-associated deaths;
(c) Influenza-associated hospitalizations; and
(d) Weekly reports of number of rapid antigen influenza positive tests and total number tested;
(25) Lead, all blood levels;
(26) Legionellosis (Legionella spp.);
(27) Leprosy/Hansen's disease (Mycobacterium leprae);
(28) Leptospirosis (Leptospira);
(29) Listeriosis (Listeria monocytogenes);
(30) Lyme disease (Borrelia burgdorferi);
(31) Malaria (Plasmodium spp.);
(32) Melioidosis (Burkholderia pseudomallei);
(33) Mumps;
(34) Pertussis (Bordetella pertussis);
(35) Pesticide-related illness and injury, acute;
(36) Psittacosis (Chlamydia psittaci);
(37) Q fever (Coxiella burnetii);
(38) Salmonellosis (Salmonella spp.);
(39) Shigellosis (Shigella spp.);
(40) Silicosis;
(41) Spotted Fever Rickettsiosis (Rickettsia spp);
(42) Streptococcus pneumoniae, invasive;
(43) Syphilis (Treponema pallidum), including primary, secondary, early latent, late latent, neurosyphilis, ocular syphilis, otosyphilis, stillbirth, and congenital;
(44) Tetanus (Clostridium tetani);
(45) Toxic shock syndrome (Streptococcal and non-Streptococcal);
(46) Transmissible spongiform encephalopathies, such as Creutzfeldt-Jakob disease;
(47) Trichinosis (Trichinella spiralis);
(48) Tuberculosis (Mycobacterium tuberculosis or Mycobacterium bovis): Latent infection in a high risk person;
(49) Typhoid (Salmonella typhi); and
(50) Vibriosis (Vibrionaceae).
Source: 20 SDR 69, effective November 17, 1993; 23 SDR 60, effective October 31, 1996; 28 SDR 92, effective December 30, 2001; 29 SDR 87, effective December 22, 2002; 30 SDR 87, effective December 7, 2003; 31 SDR 89, effective December 27, 2004; 33 SDR 106, effective December 26, 2006; 34 SDR 179, effective December 24, 2007; 38 SDR 8, effective August 1, 2011; 39 SDR 203, effective June 10, 2013; 42 SDR 77, effective November 30, 2015; 42 SDR 173, effective July 1, 2016; 45 SDR 83, effective December 17, 2018; 50 SDR 12, effective August 8, 2023.
General Authority: SDCL 34-1-17, 34-22-9, 34-22-12, 34-23-13.
Law Implemented: SDCL 34-22-9, 34-22-12, 34-23-2, 34-23-13.
